View Cart  

St. Jude Occluder Misses Endpoint, Company Gets Predicted Form 483

A A
St. Jude Medical announced Thursday that the company’s Amplatzer PFO Occluder has missed its primary endpoint in the RESPECT trial to evaluate the device’s success at reducing recurrent stroke risk.

To View This Article:

Login

Subscribe To Devices & Diagnostics Letter

Buy This Article Now

Add this article to your cart for $25.00